Randomized cross‐over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients

Background:  Studies have consistently shown the superior dosing efficiency of subcutaneous (s.c.) compared to intravenous (i.v.) erythropoietin (r‐HuEPO). Unlike r‐HuEPO, data from pivotal darbepoetin trials support s.c. and i.v. dosing equivalence, however, no blinded cross‐over randomized studies of s.c. and i.v. dose efficiency or intra‐patient variability in response have been published.

[1]  F. Locatelli,et al.  Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  P. Kerr,et al.  Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. , 2002, Kidney international.

[3]  J. Hornberger,et al.  Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  K. Lynn,et al.  Darbepoetin alfa: A new erythropoietic drug for the treatment of renal anaemia * , 2002 .

[5]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[6]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[7]  I. Macdougall,et al.  Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[8]  T. Lappin,et al.  Erythropoietin--the first 90 years. , 1996, Clinical and Laboratory Haematology.

[9]  J. Egrie,et al.  Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  J. Caro,et al.  Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. , 1992, Journal of the American Society of Nephrology : JASN.

[11]  C. Halstenson,et al.  Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta , 1991, Clinical pharmacology and therapeutics.

[12]  I. Macdougall,et al.  Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin) , 1991, Clinical pharmacokinetics.

[13]  A. Grahnén,et al.  Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure , 1990, Journal of internal medicine.

[14]  J. Adamson,et al.  Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. , 1989, The New England journal of medicine.

[15]  J. Boelaert,et al.  Comparative Pharmacokinetics of Recombinant Erythropoietin Administered by the Intravenous, Subcutaneous, and Intraperitoneal Routes in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients , 1989, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[16]  G. Coles,et al.  PHARMACOKINETICS OF RECOMBINANT HUMAN ERYTHROPOIETIN IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS , 1989, The Lancet.

[17]  R. Degowin,et al.  Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. , 1989, Annals of internal medicine.

[18]  S. Rudnick,et al.  SUBCUTANEOUS ERYTHROPOIETIN , 1988, The Lancet.

[19]  C. Whitty,et al.  Burkholderia pseudomallei infection, or melioidosis, and nephrotic syndrome. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  W. Suki,et al.  Neocytolysis contributes to the anemia of renal disease. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  L. McMahon,et al.  Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. , 1990, American journal of nephrology.